Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-Marketing, Double-Blind, Randomized Controlled Trial.

Next Previous
Trial Profile

Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-Marketing, Double-Blind, Randomized Controlled Trial.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enalapril/folic acid (Primary) ; Enalapril
  • Indications Essential hypertension; Stroke
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CSPPT

Most Recent Events

  • 12 Aug 2014 Biomarkers information updated
  • 22 Oct 2010 Planned end date changed from 1 Mar 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov
  • 22 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top